Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

  title={Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials},
  author={Naveed Sattar and David Preiss and Heather M. Murray and Paul Welsh and Brendan M. Buckley and A.J.M. de Craen and Sreenivasa Rao Kondapally Seshasai and John J. V. McMurray and Dilys J. Freeman and Johan Wouter Jukema and Peter W. Macfarlane and Chris J. Packard and David J. Stott and Rudi G. J. Westendorp and James Shepherd and Barry R. Davis and Sara L. Pressel and Roberto Marchioli and Rosa Maria Marfisi and Aldo Pietro Maggioni and Luigi Tavazzi and Gianni Tognoni and John Kjekshus and Terje Rolf Pedersen and Thomas J. Cook and Antonio M. Jr. Gotto and Michael B. Clearfield and John Richard Downs and Haruo M D Nakamura and Yasuo Ohashi and Kyoichi Mizuno and Kausik K. Ray and Ian Ford},
  journal={The Lancet},

Figures from this paper

Do statins really cause diabetes?
Investigation found that statin therapy can slightly increase risk of incident diabetes in subjects with hypercholesterolemia and subgroup analysis showed that only 2 statins namely, atorvastsatin and rosuvastatin were significantly associated.
Statin use and risk of new-onset diabetes: A meta-analysis of observational studies.
Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis
Statin treatment is associated with a modest increase in HbA1c in patients with diabetes, and this review was limited by the small number of studies, available data on only three statins and sparse reporting on changes in use of glucose-lowering medications.
Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis
It is indicated that statin therapy has cardiovascular benefit among patients with type 2 diabetes and need not change among them with moderate or high cardiovascular risk or existing cardiovascular disease.
Statins and Risk of Diabetes
In this sample of the general population, statin therapy was associated with 14% increased risk of type 2 diabetes, and differential survival did not explain this increased risk.
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis
Reductions in relative risk were similar to those seen in patients with a history of coronary artery disease, and statins were found to be efficacious in preventing death and cardiovascular morbidity in people at low cardiovascular risk.
Risk of incident diabetes among patients treated with statins: population based study
Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastsatin, might be associated with an increased risk of new onset diabetes.
Lower Intensified Target LDL-c Level of Statin Therapy Results in a Higher Risk of Incident Diabetes: A Meta-Analysis
Apart from age, female, and baseline level of total cholesterol, meta-regression analysis showed that the target and baseline levels of LDL-c and relative LDL- c reduction were predictors of statin-induced diabetes.


Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study
By lowering plasma triglyceride levels, pravastatin therapy may favorably influence the development of diabetes, but other explanations, such as the anti-inflammatory properties of this drug in combination with its endothelial effects, cannot be excluded with these analyses.
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.
Fuvastatin treatment in patients with average cholesterol levels undergoing their first successful PCI significantly reduces the risk of major adverse cardiac events.
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
Pravastatin did not reduce either all-cause mortality or CHD significantly when compared with usual care in older participants with well-controlled hypertension and moderately elevated LDL-C.